User's blog

Clinical and Operational Email – November 20th

—

by

Sadé Montgomery
in

Hi Team!

I hope you’re wrapping up the week on a strong note! We have some important updates, exciting clinical pearls, new patient support tools, and another round of incredible patient feedback to celebrate. Let’s dive in:

🩺 HTN, SOP Review — Accountability in 2026

Thank you to everyone who joined yesterday’s HTN, SOP Review. If you missed it, please be sure to review the Zoom recording and SOP.
📌 Key reminder: Starting in 2026, we’ll be held accountable for treating uncontrolled hypertension in patients using Flyte-connected devices, especially when it’s not being adequately managed by the PCP or cardiologist. We are providing critical gap care,—your role matters.

Please review the zoom recording below

🧬  GLP-1 Communication Reminders — Consistency is Key

Please do not tell S O-CT or Emory patients that their insurance has “denied access” to GLP-1 medications. This causes confusion.
📌 Reminder: Our internal medical leadership and safety teams evaluate all GLP-1 therapy on a case-by-case, individualized basis.
🚫 Do not reference our internal process as a “prior authorization.”
✅ Facing pushback? Use the attached communication framework or reach out to Kenzie or Nathan directly for support.

💊 Novo Nordisk Savings Update — Great News for Direct to Consumer Patients!

Effective November 17, 2025, new self-pay pricing is available for We-go-vee and Ozempic:

  • Standard self-pay: $349 per month (originally $499) for 0.5mg or 1 mg doses
  • Intro offer: First 2 months at $199 per month (only for 0.25mg or 0.5mg doses)
  • Ozempic 2mg remains at $499 per month

Access through:

🎯 For eligible patients with commercial insurance:

  • $0 per month for We-go-vee
  • $25 per month for Ozempic

📬 ResultsCall and Patient Portal Integration is Live

Patients will now get automated messages when test results are available in the portal.
📌 Reminder: To send a result to the portal:

  • Process result in REVIEW status
  • Choose:
    • “Notify Patient – Normal” or “Abnormal” (you may include notes regarding lab results to the patients too). 
    • “Send to portal – Email patient”

🛑 Want to publish quietly? Choose “Publish to Portal (no notification)” under More Actions.

📈 Tip: Providers can set a user preference to trigger a follow-up case if a result isn’t viewed after 2 weeks. Instructions in the full SOP.

🗣️ October Survey Shout-Outs 💥

Amazing job, team. Here’s what patients had to say:

“Amy Laktash was absolutely amazing!”
“Charlotte was very friendly and explained everything clearly.”
“Shataniel, NP and Julie, RD gave me great suggestions!”.
“Melissa Morenings was thurow and easy to understand.”
“Natalie, NP made everything feel manageable and exciting.”
“Julie, NP was phenomenal—best provider I’ve seen.”
“Eleni has been excellent.”
“Dr. Southern was wonderful.”
“Dr. Erin Jones truly understood my health needs.”

Keep up the outstanding care!

🧠 ObeesityWeek Insight — NB and Mental Health

Research shows NB (naltrexone-bupropion) is most effective in patients with comorbid depression and anxiety:

  • TBWL% at 12 months:
    • Depression and anxiety: 12.4%
    • Either depression or anxiety: 8.5%
    • Neither: 5.3%.
      🔗 Please Read Full Article
    • Please note here at FlyteHealth we strategically prefer bupropion XL over SR formulation as XL has less side effects and is once daily dosing!
    • Please review the chart shown below

💡 Case Study Highlights

📍 ID 13198.


Sixty one year old Female — Class 3 obesity, hyperlipidemia, prediabetes, TBI, depression and anxiety, OA

📉 Lost 69 pounds / 25% TBWL in 12 months.
🧑‍⚕️ Jessica Fields NP + Julie Schwartz RD
✅ Strategy: Low-dose Mounjaro + behavioral change.
👏 Fantastic work!

📍 ID 23126.


65 year old Female — Class 3 obeesity, prediabetes, right sciatica, knee pains, vitamin D – deficiency, vitamin b12 insufficiency, elevated CRP, hyperlipidemia, Graves.
📉 Lost 28 pounds / 13.1% TBWL in 12 weeks.
💊 Metformin 500mg + Bupropion 100mg
🎯 Matching eating behavior to AOM intervention = clinical success

🧪 Quick Clinical Reminders

  • S O CT patients: Weekly weights + monthly BP. If on antihypertensives → weekly BP checks. HEIGHT AND WEIGHT NEED TO BE DOCUMENTED IN VITALS SECTION OF ENCOUNTER AT ALL VISITS
  • Emory: Switch We-go-vee 2.4 to Ozempic 2mg (when in maintenance) or Mounjaro 10–12.5mg (when needing more weight loss).
  • S O CT/Emory: Qsymia and Contrave not on formulary. Use generics.
  • Monotherapy Naltrexone: Only for alcohol use disorder unless directed otherwise. When used as an adjunct, consider it 4th line!
  • No Show Workflow:
    • Wait 5 min → Call all numbers in Athena.
    • After 10 minutes (Follow Up) / 15 mins (NPV) → Mark “No Show EP” in Reason for Visit + update Billing tab.

Thank you for your continued commitment to exceptional care and raising the bar in obesity medicine. We are proud of the compassionate, evidence-based work each of you is doing.

As always, reach out with questions, ideas, or feedback.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *